Advocating for robust support of the rare disease community at large, including continued government funding for rare disease research and development, clinical trial reform to accelerate the path to new treatments, and financial incentives such as the Rare Pediatric Disease Designation and Priority Review Voucher Programs that encourage investment in this space.
2026 · 3rd Quarter (July 1 - Sep 30)
QUOIN PHARMACEUTICALS, INC.
Filed by FORWARD GLOBAL.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- $20,000.00
- Expenses
- Not reported
- Registrant
- FORWARD GLOBAL
- Filing UUID
- 63c1ed3f-0879-4152-886c-431fee38bf0c
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.